

IN THE CLAIMS:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A method of treating a subject diagnosed as having Fabry disease comprising administering to the subject a therapeutically effective amount of two or more of the following:

- a) an exogenously produced natural or recombinant lysosomal hydrolase α -galactosidase A,
- b) a gene therapy viral or non-viral vector encoding a lysosomal hydrolase, α -galactosidase A, and
- c) a small molecule such that the Fabry disease is treated.

2. (Withdrawn) The method according to claim 1 wherein the combination therapy comprises alternating between administration of an enzyme replacement therapy and a small molecule therapy.

3. (Withdrawn) The method according to claim 1 wherein the combination therapy comprises simultaneously administering an enzyme replacement therapy and a small molecule therapy.

4. (Currently amended) The method according to claim 1, wherein the combination therapy comprises administering

- a) a gene therapy viral or non-viral vector encoding a lysosomal hydrolase, α -galactosidase A and

b) one of the following: an exogenously produced natural or recombinant lysosomal hydrolase, α-galactosidase A and a small molecule therapy.

5. (Previously presented) The method according to claim 1 wherein the method of treating a subject diagnosed as having Fabry disease produces a diminution in globotriaosylceramide.

6. (Currently amended) The method according to claim 1 wherein the ~~exogenously produced natural or recombinant lysosomal hydrolase is α-galactosidase A~~ is a recombinant α-galactosidase A.

7. (Currently amended) The method according to claim 1 wherein the small molecule ~~therapy~~ comprises ~~administering to the subject~~ an effective amount of deoxynojirimycin or a deoxynojirimycin derivative.

8. (Withdrawn) The method according to claim 7, wherein the deoxynojirimycin derivative is N butyldeoxynojirimycin (NB-DNJ) or *N*-(5-adamantane-1-yl-methoxy)pentyl)-deoxynojirimycin (AMP-DNJ).

9. (Currently amended) The method according to claim 1, wherein the small molecule ~~therapy~~ comprises ~~administering to the subject~~ an effective amount of a *D-threo*-1-phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (P4) derivative.

10. (Withdrawn) The method according to claim 9, wherein the P4 derivative is *D-threo*-1-(3',4'-ethylenedioxy)phenyl-2-palmitoylamino-3-pyrrolidino-1-propanol (D-tet-P4).

11. (Currently amended) The method according to claim 1, wherein Fabry disease has at least one central nervous system manifestation and the small molecule ~~therapy~~ comprises AMP-DNJ.

12. (Currently amended) The method according to claim 1, comprising administering a therapeutically effective amount of an exogenously produced natural or recombinant ~~lysosomal hydrolase~~ α -galactosidase A and a small molecule such that the Fabry disease is treated.